Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ Ã¼¿Ü¼öÁ¤(IVF) À¯Àü À§Çè Á¡¼ö ½ÃÀåÀº 2025³â 3¾ï 6,320¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, ¿¹Ãø ±â°£ µ¿¾È 13.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2032³â±îÁö 8¾ï 8,130¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ü¿Ü¼öÁ¤(IVF) À¯Àü À§Çè Á¡¼ö(GRS)´Â ü¿Ü¼öÁ¤(IVF)¿¡ ÀÇÇØ ¸¸µé¾îÁø ¹è¾ÆÀÇ À¯ÀüÀû °ÇÀü¼ºÀ» Æò°¡ÇÏ´Â ÃÖ÷´Ü »ý½Ä ±â¼úÀÔ´Ï´Ù. ƯÁ¤ À¯ÀüÀÚ ¸¶Ä¿, ´ÜÀÏ ¿°±â ´ÙÇü¼º(SNP), ´ÙÀ¯ÀüÀÚ À§Çè ÀÎÀÚ¸¦ ºÐ¼®ÇÔÀ¸·Î½á, GRS´Â ¹è¾Æ°¡ ³ªÁß¿¡ ƯÁ¤ À¯Àü Áúȯ ¹× Áõ»óÀ» ÀÏÀ¸Å³ °¡´É¼ºÀ» ¿¹ÃøÇÕ´Ï´Ù. ÀÌ ½ºÄھ ½Ã½ºÅÛÀº ÀÓ»óÀÇ¿Í ¹Ì·¡ÀÇ ºÎ¸ð°¡ °Ç°ÇÑ Àӽа¡´É¼ºÀ» Çâ»ó½Ã۰í À¯Àü¼º ÁúȯÀÇ À§ÇèÀ» ÁÙÀ̱â À§ÇØ ¹è¾Æ ¼±Åÿ¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. IVF GRS´Â ÷´Ü À¯Àüü °úÇÐ, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¹× »ý½Ä ÀǷḦ ÅëÇÕÇÏ¿© º¸´Ù ³ôÀº Á¤¹Ðµµ ¹× ¼±°ß¼ºÀ¸·Î ºÒÀÓ Ä¡·á¸¦ °³º°ÈÇÕ´Ï´Ù.
»ý½Ä ±â¼úÀÇ Áøº¸
À¯ÀüüÇÐ, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º, ¹è¾Æ ½ºÅ©¸®´×ÀÇ ±Þ¼ÓÇÑ ±â¼ú Çõ½ÅÀº ü¿Ü¼öÁ¤(IVF) À¯Àü À§Çè Á¡¼ö(GRS)ÀÇ Ã¤¿ëÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ´ÙÀ¯ÀüÀÚ À§Çè ÀÎÀÚ ¹× ´ÜÀÏ ¿°±â ´ÙÇü¼º(SNPs)ÀÇ °ËÃâ Á¤È®µµ¸¦ Çâ»ó½ÃÅ´À¸·Î½á ÀÓ»ó°¡´Â ´õ ³ôÀº ½Å·Ú¼ºÀ¸·Î ¹è¾Æ ¼±ÅÃÀ» °³ÀÎÈÇÒ ¼ö ÀÖ½À´Ï´Ù. AI ÁÖµµ ºÐ¼®°ú Â÷¼¼´ë ½ÃÄö½Ì(NGS) Ç÷§ÆûÀÇ ÅëÇÕÀº ¿¹Ãø Á¤È®µµ¸¦ ´õ¿í Çâ»ó½Ã۰í GRS¸¦ Çö´ë ºÒÀÓ Ä¡·áÀÇ ¿äÀÎÀ¸·Î »ï°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â ÀÓ»ó °á°ú¸¦ Çâ»ó½Ã۰í À¯Àü¼º Àå¾ÖÀÇ ¹ß»ý·üÀ» °¨¼Ò½ÃÅ´À¸·Î½á ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
³ôÀº ºñ¿ë ¹× Á¦ÇÑµÈ Á¢±Ù¼º
³ôÀº ºñ¿ë ¹× Á¦ÇÑµÈ Á¢±Ù¼ºÀº ü¿Ü¼öÁ¤(IVF) À¯Àü À§Çè Á¡¼ö ½ÃÀåÀÇ ¼ºÀåÀ» ÇöÀúÇÏ°Ô ÀúÇØÇϰí ÀÖ½À´Ï´Ù. ÀÌ À庮Àº ¹æ´ëÇÑ Àα¸¸¦ Ãʱ⠴ܰèÀÇ À¯Àüü ½ºÅ©¸®´×¿¡¼ Á¦°ÅÇÏ°í °øÁ¤ÇÑ ÇコÄɾî Çõ½ÅÀ» ¹æÇØÇÕ´Ï´Ù. ½ÅÈï Áö¿ªÀÇ º¸Çè Àû¿ë°ú ÀÎÇÁ¶ó ºÎÁ·Àº °ÝÂ÷¸¦ ´õ¿í ¾ÇȽÃŰ°í ¼ö¿ä¸¦ ¾ïÁ¦Çϸç ÀÓ»ó ÅëÇÕÀ» ´ÊÃß°í ÀÖ½À´Ï´Ù. ±× °á°ú, ½ÃÀåÀÇ È®´ë´Â ¿©ÀüÈ÷ Á¦¾àÀ» ¹Þ°í, ÃæºÐÇÑ ¼ºñ½º¸¦ ¹ÞÁö ¸øÇÑ Áö¿ª¿¡¼´Â º¯ÈÀÇ °¡´É¼ºÀÌ ½ÇÇöµÇ°í ÀÖÁö ¾Ê½À´Ï´Ù.
À¯Àü¼º ÁúȯÀÇ ¹ß»ý·ü »ó½Â
³¶Æ÷¼º ¼¶À¯Áõ, Å×À̻轺, BRCA °ü·Ã ¾Ï µî À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¿¹Ãø ¹è¾Æ ½ºÅ©¸®´×¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ÈÇϰí ÀÖ½À´Ï´Ù. ü¿Ü¼öÁ¤(IVF) À¯Àü À§Çè Á¡¼ö´Â À¯ÀüÀû ¼ÒÀÎÀÇ Á¶±â ½Äº°À» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á Àû±ØÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ¿© »ý½Ä¿¡ ´ëÇÑ ÀÇ»ç °áÁ¤À» °³¼±ÇÕ´Ï´Ù. ÀÓ»óÀÇ¿Í ºÎ¸ð°¡ µÉ °ÍÀ¸·Î ¿¹»óµÇ´Â »ç¶÷µé »çÀÌÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó GRS´Â ºÒÀÓ Ä¡·á ÇÁ·ÎÅäÄÝÀÇ Ç¥ÁØ ±¸¼º¿ä¼Ò°¡ µÉ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÓ»ó ¿ä±¸ Áõ°¡´Â ƯÈ÷ À¯Àü¼º ÁúȯÀÇ ¹ß»ý·üÀÌ ³ôÀº Áö¿ª¿¡¼ Å« ¼ºÀå ±âȸ°¡ µË´Ï´Ù.
¹è¾Æ ¼Õ»óÀÇ À§Çè
À¯ÀüÀÚ °Ë»ç Áß¿¡ ¹è¾Æ°¡ ¼Õ»óµÇ´Â À§ÇèÀº ü¿Ü¼öÁ¤(IVF) À¯Àü À§Çè Á¡¼ö¿¡ ´ëÇÑ ½Å·Ú¸¦ ÇöÀúÇÏ°Ô ÀúÇØÇÏ´Â ÀÓ»ó ÀÇ»ç¿Í ºÎ¸ð Èĺ¸ »çÀÌÀÇ Ã¤¿ëÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù. ħ½ÀÀûÀÎ »ý°Ë ±â¼ú°ú »ýÁ¸ °¡´ÉÇÑ ¹è¾Æ¿¡ ´ëÇÑ ÀáÀçÀû À§Çè¿¡ ´ëÇÑ ¿ì·Á´Â À±¸®ÀûÀÌ°í ¾ÈÀü¼º¿¡ ´ëÇÑ °æÁ¾À» ¿ï¸®¸ç ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú ÅõÀÚÀÚÀÇ °ü½ÉÀ» Á¤Ã¼½Ãŵ´Ï´Ù. ÀÌ ºÒÈ®½Ç¼ºÀº ½ÃÀåÀÇ ¼ºÀåÀ» ¹æÇØÇϰí ÀÓ»ó ÅëÇÕÀ» Á¦ÇÑÇϸç, ƯÈ÷ º¸¼öÀûÀÎ »ý½Ä Á¤Ã¥°ú À¯Àüü ¸®ÅÍ·¯½Ã°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼´Â ÀÏ¹Ý ´ëÁßÀÇ È¸ÀǽÉÀ» ºÎÃß±â°í ÀÖ½À´Ï´Ù.
COVID-19ÀÇ ¿µÇâ
COVID-19ÀÇ À¯ÇàÀº ºÒÀÓ Ä¡·á Áß´Ü, ¹è¾Æ ÀÌ½Ä Áö¿¬, ȯÀÚÀÇ Á¤½ÅÀû ½ºÆ®·¹½º Áõ°¡·Î ü¿Ü¼öÁ¤(IVF) À¯Àü À§Çè Á¡¼ö ½ÃÀåÀ» È¥¶õ½ÃÄ×½À´Ï´Ù. Ŭ¸®´ÐÀº Æó¼â ±â°£ µ¿¾È ¾÷¹«¸¦ ÀϽà ÁßÁöÇÏ¿© Áֱ⠿¬±â¿Í ¼ö¿ä °¨¼Ò·Î À̾îÁ³½À´Ï´Ù. ±×·¯³ª ÀÌ À§±â´Â µðÁöÅÐ ÁøÂû°ú À¯Àüü ½ºÅ©¸®´× ÀÎÁö¸¦ °¡¼ÓÈÇϰí Àå±âÀûÀÎ ¼ºÀåÀ» °¡¼ÓÇß½À´Ï´Ù. ¼ºñ½º°¡ Àç°³µÊ¿¡ µû¶ó °³º°ÈµÈ ¹è¾Æ ¼±Åðú À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏ ¸µ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁ³°í ½ÃÀå ȸº¹°ú ±â¼ú Çõ½Å¿¡ ź·ÂÀÌ ÀÖ¾ú½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ÇüÁú ½ºÅ©¸®´× ºÐ¾ß°¡ ÃÖ´ë°¡ µÉ Àü¸Á
ÇüÁú ½ºÅ©¸®´× ºÐ¾ß´Â ´ÙÀ¯ÀüÀÚ À§Çè ¹× À¯Àü¼º ÁúȯÀÇ Æò°¡¿¡¼ ±¤¹üÀ§ÇÑ ÀÓ»óÀû À¯¿ë¼ºÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ƯÁ¤ À¯ÀüÀÚ ¸¶Ä¿¸¦ ºÐ¼®ÇÏ¸é ¸¸¼º Áúȯ, ÀÎÁö Àå¾Ö ¹× ½ÅüÀû ÀÌ»ó°ú °ü·ÃµÈ ÇüÁúÀÇ Á¶±â ¹ß°ßÀÌ °¡´ÉÇÕ´Ï´Ù. ºñħ½ÀÀûÀÌ°í ±âÁ¸ÀÇ Ã¼¿Ü¼öÁ¤(IVF) ¿öÅ©Ç÷ο쿡 ÀûÇÕÇϱ⠶§¹®¿¡ È®À强ÀÌ ³ô½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á°¡ º¸±ÞµÊ¿¡ µû¶ó ÇüÁú ½ºÅ©¸®´×Àº ¹è¾Æ ¼±º°¿¡ ÇʼöÀûÀÌ µÇ¾î ½ÃÀå Á¡À¯À²ÀÇ ÁÖµµ±ÇÀ» Àâ´Â ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ºÒÀÓ Ä¡·á Ŭ¸®´Ð ºÐ¾ß°¡ °¡Àå ³ôÀº CAGRÀÌ ¿¹»óµË´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È Á¾ÇÕÀûÀÎ »ý½Ä ÀÇ·á ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ºÒÀÓ Ä¡·á Ŭ¸®´Ð ºÐ¾ß°¡ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ Å¬¸®´ÐÀº À¯Àü »ó´ã, ¹è¾Æ ½ºÅ©¸®´× ¹× ¸ÂÃã Ä¡·á °èȹÀ» Æ÷ÇÔÇÑ Á¾´Ü °£ IVF ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. °í±Þ GRS Ç÷§ÆûÀÇ Ã¤ÅÃÀº ȯÀÚÀÇ °á°ú¸¦ Çâ»ó½Ã۰í ÀÓ»ó È¿À²À» ³ôÀÔ´Ï´Ù. À¯Àü À§Çè Á¡¼öÀÇ ÀÎÁöµµ°¡ ³ô¾ÆÁü¿¡ µû¶ó, ºÒÀÓ Ä¡·á Ŭ¸®´ÐÀº ƯÈ÷ ȯÀÚ ¼ö°¡ ¸¹°í °íµµÀÇ ½ÇÇè½Ç ´É·ÂÀ» °¡Áø µµ½Ã Áö¿ª¿¡¼ Áß¿äÇÑ ÆÇ¸Å ä³Î·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀº È®´ëµÇ´Â ºÒÀÓÄ¡·á ÀÎÇÁ¶ó, À¯Àü¼º Áúȯ¿¡ ´ëÇÑ ÀÇ½Ä °íÁ¶ ¹× Á¤ºÎÀÇ Áö¿øÃ¥À¸·Î ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áß±¹, Àεµ, ÀϺ» µî ±¹°¡¿¡¼´Â Àα¸ µ¿ÅÂÀÇ º¯È ¹× Áß°£ÃþÀÇ °æÁ¦Àû ¿©À¯ È®´ë·Î ü¿Ü¼öÁ¤(IVF)ÀÇ µµÀÔÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À¯ÀüüÇÐ ¹× µðÁöÅÐ °Ç°¿¡ ´ëÇÑ Áö¿ª ÅõÀÚ´Â GRS ÅëÇÕÀ» ´õ¿í °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ºÒÀÓ Ä¡·á Ŭ¸®´Ð°ú ¿¬±¸ ±â°üÀÇ Á¸Àç·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¼¼°è IVF GRS Àü¸Á¿¡¼ Áö¹èÀû ¼¼·ÂÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì´Â °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À̰ÍÀº °ß°íÇÑ ÇコÄɾî ÀÎÇÁ¶ó, ³ôÀº ȯÀÚ ÀǽÄ, À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ °·ÂÇÑ ±ÔÁ¦ Áö¿ø ¶§¹®ÀÔ´Ï´Ù. ÀÌ Áö¿ªÀº Á¤¹ÐÀÇ·á¿Í °í±Þ ü¿Ü¼öÁ¤(IVF) ÇÁ·ÎÅäÄÝÀ» ÀÏÂïºÎÅÍ Ã¤¿ëÇϰí ÀÖÀ¸¸ç, GRS È®´ë¸¦ À§ÇÑ ºñ¿ÁÇÑ Åä¾çÀÌ µÇ°í ÀÖ½À´Ï´Ù. »ý¸í °øÇÐ ±â¾÷°ú ºÒÀÓ Ä¡·á ¼¾ÅÍ °£ÀÇ Àü·«Àû Á¦ÈÞ´Â ±â¼ú Çõ½Å°ú Á¢±Ù¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. È£ÀÇÀûÀÎ »óȯÁ¤Ã¥ ¹× °³º°ÈµÈ »ý½ÄÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ÀÖ¾î ºÏ¹ÌÀÇ ¸®´õ½ÊÀ» À¯ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
According to Stratistics MRC, the Global IVF Genetic Risk Scoring Market is accounted for $363.2 million in 2025 and is expected to reach $881.3 million by 2032 growing at a CAGR of 13.5% during the forecast period. IVF Genetic Risk Scoring (GRS) is a cutting-edge reproductive technology that evaluates the genetic health of embryos created through in vitro fertilization (IVF). By analyzing specific genetic markers, single-nucleotide polymorphisms (SNPs), and polygenic risk factors, GRS predicts the likelihood of an embryo developing certain inherited diseases or conditions later in life. This scoring system enables clinicians and prospective parents to make informed decisions about embryo selection, aiming to improve the chances of a healthy pregnancy and reduce the risk of genetic disorders. IVF GRS integrates advanced genomics, bioinformatics, and reproductive medicine to personalize fertility care with greater precision and foresight.
Advancements in Reproductive Technologies
Rapid innovations in genomics, bioinformatics, and embryo screening are propelling the adoption of IVF Genetic Risk Scoring (GRS). Enhanced precision in detecting polygenic risk factors and single-nucleotide polymorphisms (SNPs) enables clinicians to personalize embryo selection with greater confidence. Integration of AI-driven analytics and next-generation sequencing (NGS) platforms is further improving predictive accuracy, making GRS a cornerstone of modern fertility care. These advancements are driving market expansion by elevating clinical outcomes and reducing the incidence of inherited disorders.
High Cost and Limited Accessibility
High cost and limited accessibility significantly hinder the growth of the IVF genetic risk scoring market by restricting adoption to affluent urban centers. These barriers exclude vast populations from early-stage genomic screening, stalling equitable healthcare innovation. The lack of insurance coverage and infrastructure in emerging regions further exacerbates disparities, curbing demand and slowing clinical integration. As a result, market expansion remains constrained, with transformative potential unrealized across underserved geographies.
Rising Incidence of Genetic Disorders
The increasing prevalence of hereditary conditions such as cystic fibrosis, Tay-Sachs, and BRCA-related cancers is intensifying demand for predictive embryo screening. IVF Genetic Risk Scoring offers a proactive solution by enabling early identification of genetic predispositions, thereby improving reproductive decision-making. As awareness grows among clinicians and prospective parents, GRS is poised to become a standard component of fertility protocols. This rising clinical need presents a significant growth opportunity, especially in regions with high rates of inherited diseases.
Risk of Embryo Damage
The risk of embryo damage during genetic testing significantly undermines confidence in IVF genetic risk scoring, deterring adoption among clinicians and prospective parents. Concerns over invasive biopsy techniques and potential harm to viable embryos raise ethical and safety alarms, stalling regulatory approvals and investor interest. This uncertainty hampers market growth, limits clinical integration, and fuels public skepticism, especially in regions with conservative reproductive policies and limited genomic literacy.
Covid-19 Impact
The COVID-19 pandemic disrupted the IVF Genetic Risk Scoring market by halting fertility treatments, delaying embryo transfers, and increasing emotional stress for patients. Clinics paused operations during lockdowns, leading to postponed cycles and reduced demand. However, the crisis accelerated digital consultations and genomic screening awareness, fostering long-term growth. As services resumed, heightened interest in personalized embryo selection and genetic profiling positioned the market for resilient recovery and innovation.
The trait screening segment is expected to be the largest during the forecast period
The trait screening segment is expected to account for the largest market share during the forecast period, due to its broad clinical utility in assessing polygenic risks and inherited conditions. By analyzing specific genetic markers, this segment enables early detection of traits linked to chronic diseases, cognitive disorders, and physical anomalies. Its non-invasive nature and compatibility with existing IVF workflows make it highly scalable. As personalized medicine gains traction, trait screening is becoming integral to embryo selection, driving its leadership in market share.
The fertility clinics segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the fertility clinics segment is predicted to witness the highest growth rate, due to rising demand for integrated reproductive services. These clinics offer end-to-end IVF solutions, including genetic counseling, embryo screening, and personalized treatment plans. Their adoption of advanced GRS platforms enhances patient outcomes and boosts clinical efficiency. As awareness of genetic risk scoring grows, fertility clinics are emerging as key distribution channels, particularly in urban centers with high patient volumes and advanced lab capabilities.
During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its expanding fertility infrastructure, rising awareness of genetic disorders, and supportive government initiatives. Countries like China, India, and Japan are witnessing increased IVF adoption, driven by demographic shifts and growing middle-class affordability. Regional investments in genomics and digital health are further accelerating GRS integration. The presence of leading fertility clinics and research institutions positions Asia Pacific as a dominant force in the global IVF GRS landscape.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust healthcare infrastructure, high patient awareness, and strong regulatory support for genetic testing. The region's early adoption of precision medicine and advanced IVF protocols makes it fertile ground for GRS expansion. Strategic collaborations between biotech firms and fertility centers are enhancing innovation and accessibility. Favorable reimbursement policies and growing demand for personalized reproductive care are expected to sustain North America's leadership in market growth.
Key players in the market
Some of the key players profiled in the IVF Genetic Risk Scoring Market include Illumina, Inc., Agilent Technologies, Inc., Natera, Inc., CooperSurgical, Inc., Thermo Fisher Scientific, Inc., Vitrolife AB, Igenomix, Genea Limited, PerkinElmer, Inc., Quest Diagnostics Incorporated, Invicta Genetics, Juno Genetics, US Inc., Bioarray S.L., Reproductive Health Science Ltd. and Genesis Genetics Ltd.
In July 2025, Thermo Fisher Scientific has agreed to acquire Sanofi's sterile manufacturing site in Ridgefield, New Jersey. This expansion aims to bolster U.S. drug product manufacturing capabilities, enhancing capacity to meet the increasing demand from pharmaceutical and biotech customers.
In July 2020, PerkinElmer partnered with Sonora Quest Laboratories to expand COVID-19 testing in Arizona. This collaboration aimed to increase testing capacity in response to rising case numbers, supported by funding from the state of Arizona.